AngioDynamics reported second-quarter earnings that matched analysts’ expectations on a per-share basis while delivering an 8.8% year-over-year revenue increase. Revenue climbed to $77.8 million, driven primarily by strong performance in the Med Tech segment, which saw sales growth of 12.5%. The company’s gross margin expanded by 170 basis points to 51.3%, reflecting improved production efficiencies and favorable product mix in its vascular access portfolio. Operating expenses remained flat at $28.4 million, supported by disciplined cost management across R&D and SG&A functions.

In the third quarter, AngioDynamics generated $79.4 million in revenue, surpassing the consensus estimate of $76.4 million. The year-over-year increase of 8.8% was sustained by higher unit volumes in the peripheral intervention line and new product sales in the oncology segment. On an adjusted basis, the company delivered a net operating result near breakeven, reporting an adjusted loss of only $59,000 compared with an expected loss of $1.2 million. Adjusted EBITDA improved to $10.5 million, up from $7.8 million a year earlier, reflecting continued leverage on fixed costs.

Despite strong fundamentals, AngioDynamics shares declined by 13.1% following the announcement of CEO Jim Clemmer’s unexpected retirement after a decade at the helm. The board has convened a search committee with an external executive search firm to identify a successor, leaving investors concerned about leadership continuity. Clemmer will remain in his role until a new chief executive is appointed. In conjunction with the transition, the company raised its full-year 2026 net sales guidance to a range of $310 million to $315 million and boosted adjusted EBITDA projections to $48 million–$52 million, reflecting confidence in the underlying business momentum.